Company profile
Liquidia Corp
NASDAQ:LQDABiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Treprostinil | approved | — | 7 | approved |
| Treprostinil sodium | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07285655 | phase3 | recruiting | 2026-04-23 | 2029-07-01 | Liquidia Technologies, Inc. | A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD |
| NCT01224262 | phase1_2 | completed | 2010-09-01 | 2011-12-01 | Liquidia Technologies, Inc. | A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 |
| NCT03992755 | phase3 | active_not_recruiting | 2019-07-18 | 2025-05-31 | Liquidia Technologies, Inc. | Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil |
| NCT03884465 | phase2 | terminated | 2019-11-11 | 2020-12-23 | Liquidia Technologies, Inc. | Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil |
| NCT03399604 | phase3 | completed | 2018-01-02 | 2019-05-06 | Liquidia Technologies, Inc. | Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 213005 | NDA | LIQUIDIA TECHNOLOGIES INC | ||||
Loading… | ||||||